T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer

NCT04611126 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped Slow recruitment

Conditions

Metastatic Ovarian Cancer
Metastatic Fallopian Tube Cancer
Peritoneal Cancer

Interventions

DRUG: Ipilimumab
DRUG: Cyclophosphamid
DRUG: Fludarabine Phosphate
BIOLOGICAL: Tumor Infiltrating Lymphocytes infusion
DRUG: Nivolumab
DRUG: Relatlimab

Sponsor

Inge Marie Svane